Market Overview

Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen

Share:
Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Biotech Stocks Hitting 52-week highs on April 24)

  • Eleven Biotherapeutics Inc (NASDAQ: EBIO)

Down In The Dumps

(Biotech Stocks Hitting 52-week lows on April 24)

  • Acasti Pharma Inc (NASDAQ: ACST) on announcing pricing of a common stock offering
  • BioXcel Therapeutics Inc (NASDAQ: BTAI)
  • Conatus Pharmaceuticals Inc (NASDAQ: CNAT)
  • Paratek Pharmaceuticals Inc (NASDAQ: PRTK)
  • Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Takeda's Relentless Pursuit For Shire

Shire PLC (ADR) (NASDAQ: SHPG) shares rallied 5.64 percent to $173.18 after hours Tuesday, adding to their 2.41 percent advance in the regular session. Japan's Takeda Pharmaceutical Co Ltd (OTC: TKPHF) sweetened its cash and stock offer for the Irish pharma company for the fifth time, raising the offer this time around from $60 billion to $64.3 billion.

Shire's willingness to consider the proposal, contingent on certain conditions being met, suggest it may be finally coming around.

Edward Lifesciences Plunges On Weak Guidance

Edwards Lifesciences Corp (NYSE: EW) shares took a tumble in after hours Tuesday after it reported Q1 adjusted sales of $938 million, up 9.3 percent year-over-year, and adjusted earnings per share of $1.22, up 29.8 percent.

The company raised its 2018 adjusted earnings per share guidance from $4.43-$4.63 to $4.50-$4.70, while issuing downbeat Q2 guidance.

Sangamo Dips On Common Stock Offering

Sangamo Therapeutics Inc (NASDAQ: SGMO) shares were off 6.77 percent at $16.60 after hours Tuesday after the company announced a $200-million common stock offering.

Amgen Shares Trip Despite Beat

Amgen, Inc. (NASDAQ: AMGN) fell by 0.55 percent to $171 in after hours after it reported better-than-expected Q1 results, thanks to strong product sales and a lower tax rate. The company raised the lower-end of its full-year revenue and earnings per share guidance.

More Trouble For Menlo as Japanese Study Halted

Menlo Therapeutics Inc (NASDAQ: MNLO), which saw its stock plummet 77 percent on April 9 on a failed Phase 2 study of its skin condition treatment seriopitant, came under pressure yet again. The stock was down 9.49 percent to $7.25 after its Japanese partner JT Torii decided to halt the recently initiated Phase 2 study of seriopitant in Japan.

On The Radar

The following companies report earnings on Wednesday:

  • Integra Lifesciences Holdings Corp (NASDAQ: IART) - Q1 Adj. EPS $0.58 Beats $0.49 Est., Sales $357.1M Beats $349.1M Est.
  • The Medicines Company (NASDAQ: MDCO) - Q1 EPS $(0.76) Beats $(0.78) Est., Sales $7.77M Misses $7.99M Est.
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) – Expectations call for EPS of $(0.18), Sales of $348.57M

Related Links:

The Week Ahead In Biotech: PDUFA Dates, IPOs And More

'We Expect A Quick Resolution': Despite Partial Clinical Hold On Epizyme's Drug Candidate, Wedbush Stays Bullish

Posted-In: Biotech Earnings News Health Care FDA Top Stories Pre-Market Outlook Movers Best of Benzinga

 

Related Articles (AMGN + ACST)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

F5 Networks Q2 Earnings Preview

A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street